Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer

Simple item page
dc.contributor.authorAltan, Mehmet
dc.contributor.authorKidwell, Kelley M.
dc.contributor.authorPelekanou, Vasiliki
dc.contributor.authorSchalper, Kurt A.
dc.contributor.authorToki, María I.
dc.contributor.authorThomas, Dafydd G.
dc.contributor.authorSabel, Michael S.
dc.contributor.authorHayes, Daniel F.
dc.contributor.authorRimm, David L.
dc.contributor.authorCarvajal-Hausdorf, Daniel
dc.date.accessioned2022-05-02T20:11:13Z
dc.date.available2022-05-02T20:11:13Z
dc.date.issued2018
dc.description.abstractB7-H4 (VTCN1) is a member of the CD28/B7 family of immune co-inhibitory molecules. The relationship of tumor and stromal B7-H4 protein expression with PD-L1, tumor infiltrating lymphocytes (TILs) and its association with clinico-pathological variables are not well defined. Herein, we explore the expression level of B7-H4 protein in breast cancer and evaluate its association with TILs, levels of PD-L1 expression, and clinico-pathological characteristics in two independent populations. In this study, we used multiplexed automated quantitative immunofluorescence (QIF) to measure the levels of B7-H4 and PD-L1 protein and determined TILs through pathologist assessment of H&E-stained preparations in over a thousand breast cancer cases from two institutions represented in tissue microarray format. Associations between the marker levels, major clinico-pathological variables, and survival were analyzed. We detected B7-H4 protein was highly expressed in both breast cancer and stromal cells. Its expression was independent of breast cancer intrinsic subtypes. PD-L1 expression was higher in triple negative breast cancers. Neither B7-H4 nor PD-L1 were associated with survival in breast cancer. Our study shows there is a mutually exclusive pattern of B7-H4 with both tumor PD-L1 expression and TILs in all breast cancers, independent of breast cancer intrinsic subtype. This exclusive pattern suggests that some breast tumors may preferentially use one B7-related immune evasion mechanism/pathway. This could explain the clinical benefit that is seen only in a fraction of patients with immune checkpoint inhibitors directed exclusively towards PD-L1 in breast cancer.es
dc.description.versionVersión Publicadaes
dc.identifier.citationAltan, M., Kidwell, K.M., Pelekanou, V. et al. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. npj Breast Cancer 4, 40 (2018). https://doi.org/10.1038/s41523-018-0095-1es
dc.identifier.urihttps://doi.org/10.1038/s41523-018-0095-1es
dc.identifier.urihttp://hdl.handle.net/11447/6040
dc.language.isoenes
dc.subjectBreast canceres
dc.subjectTumour immunologyes
dc.titleAssociation of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast canceres
dc.typeArticlees
dcterms.sourcenpj Breast Canceres

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services